In an interview with Pharmacy Times, City of Hope researchers discuss a preclinical platform designed to redirect CAR T cells after infusion and how pharmacists could help bring this adaptable approach into clinical practice.
|Videos|December 13, 2021
Studies Show Acalabrutinib Is Well-Tolerated in Patients with CLL
Most adverse effects are very tolerable and easily managed, including headaches, diarrhea, and some neutropenias or infections
Advertisement
In an interview with Pharmacy Times, Niko Andre, MD, PhD, global franchise head of hematology and immuno-oncology at AstraZeneca, discussed exciting new findings being presented at the American Society of Hematology 2021 Annual Meeting about adverse effects associated with acalabrutinib in patients with chronic lymphocytic leukemia (CLL).
Andre said most adverse effects are very tolerable and easily managed, including headaches, diarrhea, and some neutropenias or infections. However, researchers found much lower rates of hypertension, cardiac arrhythmias, and bleeding events compared to what would be seen in earlier versions of the molecule class.
Newsletter
Stay informed on drug updates, treatment guidelines, and pharmacy practice trends—subscribe to Pharmacy Times for weekly clinical insights.
SubscribeAdvertisement
Related to this article
In an interview with Pharmacy Times, LINKER-SMM1 study investigator Paula Rodríguez-Otero, MD, PhD, a hematologist at Clínica Universidad de Navarra in Pamplona, Spain, explains how researchers selected high-risk patients and how she weighs infections against the potential to prevent progression to active disease.
September’s hematology coverage examined a new definition of myeloma cure, patient preferences for treatment delivery, and emerging strategies for deepening responses.
The first AHA endocarditis update in 11 years expands outpatient options, with a bigger role for pharmacists.
Investigational inhaled stem cells for COPD raise questions about lasting clinical benefit and the pharmacy controls needed to deliver a living-cell product through a nebulizer.
A suspected plague death in Russia has renewed attention on the rare infection. Here's how to spot pneumonic plague, and which antibiotics the CDC recommends.
In an interview with Pharmacy Times, Abdulkader Rahmo, PhD, discusses investigational inhaled cell therapy for COPD, the evidence needed to establish lasting clinical benefit, and pharmacists’ potential role in its delivery.
Pharmacists can explain the evidence supporting the intramuscular injection, address specific concerns, and help families understand what is known—and what is not known—about oral vitamin K.
Advertisement
Advertisement
Trending on Pharmacy Times
1
Rising Gallbladder Complications With GLP-1 Receptor Agonists Call for Closer Pharmacist Monitoring
2
The Value of Self-Monitoring Blood Glucose Tools in Preventing and Reducing Prediabetes and Diabetes-Related Complications
3
Using CKDintercept to Build Interdisciplinary Kidney Care
4
2026 AHA Endocarditis Guidelines Expand Outpatient Antibiotic Options
5